☰Menu

Oral Drug to Reduce MS Relapses FDA Approved

Author: U.S. Food and Drug Administration
Published: 2010/09/22
Category Topic: FDA - Related Publications

Page Content: Synopsis - Introduction - Main

Synopsis: FDA has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

Introduction

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

Main Content

"Gilenya is the first oral drug that can slow the progression of disability and reduce the frequency and severity of symptoms in MS, offering patients an alternative to currently available injectable therapies," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.

Gilenya is the first in a new class of drugs that block some blood cells in lymph nodes, reducing their migration to the brain and spinal cord, which may help with reducing the severity of MS.

MS is a chronic, often disabling, disease that affects the central nervous system the brain, spinal cord, and optic nerves. According to the National Multiple Sclerosis Society, there are about 400,000 people in the United States and 2.1 million people worldwide with MS.

The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. Symptoms can be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision.

Patients using Gilenya should be monitored for a decrease in heart rate upon starting the drug. Gilenya may also increase the risk of infections. Cases of serious eye problems (macular edema) have occurred in patients taking the drug and an ophthalmologic evaluation is recommended.

The most frequent adverse reactions reported by patients taking Gilenya in clinical trials include headache, influenza, diarrhea, back pain, elevation of certain liver enzymes and cough.

The drug will be available in 0.5 milligram capsules. Gilenya is made by Novartis, Basel, Switzerland.

For more information:

National Institute of Neurological Disorders and Stroke: Multiple Sclerosis Information

www.ninds.nih.gov/disorders/multiple_sclerosis/multiple_sclerosis.htm

Media Inquiries: Sandy Walsh, 301-796-4669; sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

Related Publications

• : Cognoa ASD Diagnosis Aid is an aid for diagnosis of ASD in patients 18 months - 5 years of age who are at risk of developmental delay based on concerns of a parent, caregiver, or health care provider.

• : U.S. FDA authorizes marketing of Neurolutions IpsiHand Upper Extremity Rehabilitation System to facilitate muscle rehabilitation in stroke patients.

• : U.S. FDA completes series of actions on review of OTC antiseptic active ingredients and issues final rule on safety and effectiveness of consumer hand sanitizers.

▶ Share Page
APA: U.S. Food and Drug Administration. (2010, September 22). Oral Drug to Reduce MS Relapses FDA Approved. Disabled World (DW). Retrieved January 13, 2026 from www.disabled-world.com/medical/pharmaceutical/fda/ms-relapse-drug.php
MLA: U.S. Food and Drug Administration. "Oral Drug to Reduce MS Relapses FDA Approved." Disabled World (DW), 22 Sep. 2010. Web. 13 Jan. 2026. <www.disabled-world.com/medical/pharmaceutical/fda/ms-relapse-drug.php>.
Chicago: U.S. Food and Drug Administration. "Oral Drug to Reduce MS Relapses FDA Approved." Disabled World (DW). September 22, 2010. www.disabled-world.com/medical/pharmaceutical/fda/ms-relapse-drug.php.

While we strive to provide accurate, up-to-date information, our content is for general informational purposes only. Please consult qualified professionals for advice specific to your situation.